Zobrazeno 1 - 10
of 181
pro vyhledávání: '"Daniel Rayson"'
Publikováno v:
Breast, Vol 75, Iss , Pp 103715- (2024)
Purpose: It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing. Methods: We conducted a retrospective review of cases referred for ODX testing
Externí odkaz:
https://doaj.org/article/e828222e541148968de703595fd683ab
Autor:
Jan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, Stephen Chia, Shane Shapera, Micheal McInnis, Daniel Rayson, Jamil Asselah
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8019-8038 (2023)
Ongoing advances in precision cancer therapy have increased the number of molecularly targeted and immuno-oncology agents for a variety of cancers, many of which have been associated with a risk of pulmonary complications, among the most concerning b
Externí odkaz:
https://doaj.org/article/326b83ae6cc04c08964475354e707914
Autor:
Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5050-5053 (2023)
We appreciate the opportunity to respond to the comment [...]
Externí odkaz:
https://doaj.org/article/ec2922d259024378bc8588c63bddf687
Autor:
Margaret Sheridan, Bruce Colwell, Nathan W. D. Lamond, Robyn Macfarlane, Daniel Rayson, Stephanie Snow, Lori A. Wood, Ravi Ramjeesingh
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 3149-3159 (2023)
(1) Background: Cancer is the leading cause of death in Canada, with significant resource limitation impacting the delivery of cancer care nationwide. The onset of the COVID-19 pandemic forced additional resource restriction and diversion, further im
Externí odkaz:
https://doaj.org/article/82bc1cd275b64db0ba97d61752f45889
Autor:
Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9891-9895 (2022)
The addition of pertuzumab to neoadjuvant trastuzumab and chemotherapy for women with early-stage, high-risk, HER2+ breast cancer has been observed to lead to higher pathologic complete response rates (pCR), and improved event-free survival compared
Externí odkaz:
https://doaj.org/article/8328144413f246ccbb85b8ba358777b4
Autor:
Christine Simmons, Daniel Rayson, Anil Abraham Joy, Jan-Willem Henning, Julie Lemieux, Heather McArthur, Paul B. Card, Rebecca Dent, Christine Brezden-Masley
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Evidence to date supports continued human epidermal growth factor receptor 2 (HER2) suppression beyond progression on HER2-directed therapy for advanced HER2-positive breast cancer. Data from several phase II and III trials evaluating HER
Externí odkaz:
https://doaj.org/article/ee6eca97986a4093b7725164280d86a9
Autor:
Stephen K. Chia, David W. Cescon, Andrew D. Redfern, Danielle Rodin, Christine Simmons, Jean-Pierre Ayoub, Haji Ibrahim Chalchal, Daniel Rayson, Moira Rushton-Marovac, Tracey Hay, Lisa Gallinaro, Bingshu Chen, Wendy Parulekar
Publikováno v:
Cancer Research. 83:OT3-26
Background: The PI3K/AKT/mTOR pathway is a rational target in the metastatic disease setting for hormone receptor positive breast cancer based on preclinical and clinical data demonstrating that pathway inhibition improves outcome (Baselga 2012, Andr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aefeb9be3283f0b23b5368cc50553be2
https://doi.org/10.1158/1538-7445.sabcs22-ot3-26-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-26-01
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237308 (2020)
The isolation and analysis of circulating tumor cells (CTC) has the potential to provide minimally invasive diagnostic, prognostic and predictive information. Widespread clinical implementation of CTC analysis has been hampered by a lack of comparati
Externí odkaz:
https://doaj.org/article/c0c50f5364e84496ac8f1399137b37e0
Autor:
Yue Yin Xia, Jacek Gronwald, Beth Karlan, Jan Lubinski, Jeanna M. McCuaig, Jennifer Brooks, Pal Moller, Andrea Eisen, Sophie Sun, Leigha Senter, Louise Bordeleau, Susan L. Neuhausen, Christian F. Singer, Nadine Tung, William D. Foulkes, Ping Sun, Steven A. Narod, Joanne Kotsopoulos, Rinat Yerushalmi, Robert Fruscio, Antonella Rastelli, Stefania Zovato, Zerin Hyder, Tomasz Huzarski, Cezary Cybulski, Kevin Sweet, Marie Wood, Wendy McKinnon, Christine Elser, Tuya Pal, Georgia Wiesner, Eitan Friedman, Wendy Meschino, Carrie Snyder, Kelly Metcalfe, Aletta Poll, Nicole Gojska, Ellen Warner, Raymond H. Kim, Barry Rosen, Rochelle Demsky, Peter Ainsworth, Karen Panabaker, Linda Steele, Howard Saal, Kim Serfas, Seema Panchal, Carey A. Cullinane, Robert E. Reilly, Joanne L. Blum, Ava Kwong, Daniel Rayson, Claudine Isaacs, Teresa Ramón y Cajal, Jeffrey Dungan, Stephanie Cohen
Publikováno v:
Gynecologic Oncology. 164:514-521
Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf30f48f5423bb85725814f17ef8fc7
https://doi.org/10.1016/j.ygyno.2022.01.014
https://doi.org/10.1016/j.ygyno.2022.01.014
Autor:
Penelope J. Barnes, Ryan C DeCoste, Michael D. Carter, Noreen M. Walsh, Aleodor A. Andea, Daniel Rayson, Min Wang
Publikováno v:
Journal of Cutaneous Pathology. 48:1397-1403
Cutaneous apocrine carcinomas share common features with their counterparts in the breast; hence, metastatic mammary carcinoma must be excluded before such lesions can be designated primary cutaneous neoplasms. Primary tumors from either source rarel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d1593f67cdb01f3751baed38373e6a
https://doi.org/10.1111/cup.14085
https://doi.org/10.1111/cup.14085